<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METHERGINEÂ - methylergonovine maleateÂ tablet, coatedÂ </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<h1>Methergine</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First">
		Â Â Â Â Â 
	T2006-91</p>
<p><span class="Bold">
		Â Â Â Â Â 
	Methergine</span><span class="Bold"><span class="Sup">Â®</span></span></p>
<p><span class="Bold Italics">
		Â Â Â Â Â 
	(methylergonovine maleate)</span></p>
<p><span class="Bold">
		Â Â Â Â Â 
	Tablets, USP</span></p>
<p><span class="Bold Italics">
		Â Â Â Â Â 
	(methylergonovine maleate)</span></p>
<p><span class="Bold">
		Â Â Â Â Â 
	Injection, USP</span></p>
<p><span class="Bold">
		Â Â Â Â Â 
	Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Methergine<span class="Sup">Â®</span><span class="Sup">Â </span>(methylergonovine maleate) is a semi-synthetic ergot alkaloid used for the prevention and controlÂ of <span class="product-label-link" type="condition" conceptid="443929" conceptname="Postpartum hemorrhage">postpartum hemorrhage</span>.</p>
<p>
		Â Â Â Â Â 
	Methergine is available in sterile ampuls of 1 mL, containing 0.2Â mg methylergonovine maleate for intramuscular or intravenous injection and in tablets for oral ingestion containing 0.2 mg methylergonovine maleate.</p>
<p><span class="Bold">Tablets</span></p>
<p><span class="Italics">Active Ingredient:</span>  methylergonovine maleate, USP, 0.2 mg.</p>
<p><span class="Italics">Inactive Ingredients:  </span>acacia, carnauba wax, D&amp;C Red #7, FD&amp;C Blue #1, gelatin special, lactose, maleic acid, mixed parabens, povidone, sodium benzoate, sodium hydroxide, starch, stearic acid, sucrose, talc, and titanium dioxide.</p>
<p><span class="Bold">Ampuls</span>, 1 mL, clear, colorless solution.</p>
<p><span class="Italics">Active Ingredient:</span>  methylergonovine maleate, USP, 0.2 mg.</p>
<p><span class="Italics">Inactive Ingredients: </span> maleic acid, 0.10 mg; sodium chloride, 7.0 mg; water for injection, qs to 1 mL.</p>
<p>
		Â Â Â Â Â 
	Chemically, methylergonovine maleate is designated as ergoline-8-carboxamide, 9,10-didehydro-<span class="Italics">N</span>-[1-(hydroxymethyl)propyl]-6-methyl-, [8Î²(<span class="Italics">S</span>)]-, (<span class="Italics">Z</span>)-2-butenedioate (1:1) (salt).</p>
<p>
		Â Â Â Â Â 
	Its structural formula is</p>
<div class="Figure"><img alt="Methylergonovine maleate structural formula.
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=94c9b1cf-ae12-45f3-8fcb-708a922cbc10&amp;name=methergine-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Methergine<span class="Sup">Â®</span> (methylergonovine maleate) acts directly on the smooth muscle of the uterus and increases the tone, rate, and amplitude of rhythmic contractions. Thus, it induces a rapid and sustained tetanic uterotonic effect which shortens the third stage of labor and reduces blood loss. The onset of action after I.V. administration is immediate; after I.M. administration, 2-5 minutes, and after oral administration, 5-10 minutes.</p>
<p>
		Â Â Â Â Â 
	Pharmacokinetic studies following an I.V. injection have shown that methylergonovine is rapidly distributed from plasma to peripheral tissues within 2-3 minutes or less. The bioavailability after oral administration was reported to be about 60% with no accumulation after repeated doses. During delivery, with intramuscular injection, bioavailability increased to 78%. Ergot alkaloids are mostly eliminated by hepatic metabolism and excretion, and the decrease in bioavailability following oral administration is probably a result of first-pass metabolism in the liver.</p>
<p>
		Â Â Â Â Â 
	Bioavailability studies conducted in fasting healthy female volunteers have shown that oral absorption of a 0.2 mg methylergonovine tablet was fairly rapid with a mean peak plasma concentration of 3243 Â± 1308 pg/mL observed at 1.12 Â± 0.82 hours. For a 0.2 mg intramuscular injection, a mean peak plasma concentration of 5918 Â± 1952 pg/mL was observed at 0.41 Â± 0.21 hours. The extent of absorption of the tablet, based upon methylergonovine plasma concentrations, was found to be equivalent to that of the I.M. solution given orally, and the extent of oral absorption of the I.M. solution was proportional to the dose following administration of 0.1, 0.2, and 0.4 mg. When given intramuscularly, the extent of absorption of Methergine solution was about 25% greater than the tablet. The volume of distribution (Vd<span class="Sub">ss</span>/F) of methylergonovine was calculated to be 56.1 Â± 17.0 liters, and the plasma clearance (CLp/F) was calculated to be 14.4 Â± 4.5 liters per hour. The plasma level decline was biphasic with a mean elimination half-life of 3.39 hours (range 1.5 to 12.7 hours). A delayed gastrointestinal absorption (T<span class="Sub">max</span> about 3 hours) of Methergine tablet might be observed inÂ postpartum women during continuous treatment withÂ this oxytocic agent.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">For routine management after delivery of the placenta; postpartum atony and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span>; toxemia; pregnancy; and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">This drug should not be administered I.V. routinely because of the possibility of inducing sudden hypertensive and <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">cerebrovascular accidents</span>. If I.V. administration is considered essential as a lifesaving measure, Methergine<span class="Sup">Â®</span> (methylergonovine maleate) should be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure. Intra-arterial or periarterial injection should be strictly avoided.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="section-7.1"></a><p></p>
<h2><span class="Bold">General</span></h2>
<p class="First">Caution should be exercised in the presence of <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, obliterative vascular disease, hepatic or renal involvement. Also use with caution during the second stage of labor. The necessity for manual removal of a <span class="product-label-link" type="condition" conceptid="4003030" conceptname="Retained placenta">retained placenta</span> should occur only rarely with proper technique and adequate allowance of time for its spontaneous separation.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.2"></a><p></p>
<h2><span class="Bold">Drug Interactions</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2.1"></a><p></p>
<h3>
<span class="Bold Italics">CYP 3A4 Inhibitors (e.g.</span><span class="Bold Italics">,</span><span class="Bold Italics"> Macrolide Antibiotics and Protease Inhibitors)</span>
</h3>
<p class="First">There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g., dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> leading to <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span> and/or <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span> of the extremities. Although there have been no reports of such interactions with methylergonovine alone, potent CYP 3A4 inhibitors should not be coadministered with methylergonovine. Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). Less potent CYP 3A4 inhibitors should be administered with caution. Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. These lists are not exhaustive, and the prescriber should consider the effects on CYP 3A4 of other agents being considered for concomitant use with methylergonovine.</p>
<p>
		Â Â Â Â Â 
	No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> involving other cytochrome P450 isoenzymes are known.</p>
<p>
		Â Â Â Â Â 
	Caution should be exercised when Methergine<span class="Sup">Â®</span> (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.</p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.3"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility</span></h2>
<p class="First">No long-term studies have been performed in animals to evaluate carcinogenic potential. The effect of the drug on mutagenesis or fertility has not been determined.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.4"></a><p></p>
<h2><span class="Bold">Pregnancy</span></h2>
<p class="First"><span class="Bold Italics">Category C.</span> Animal reproductive studies have not been conducted with Methergine. It is also not known whether methylergonovine maleate can cause fetal harm or can affect reproductive capacity. Use of Methergine Â is contraindicated during pregnancy because of its uterotonic effects. (See INDICATIONS AND USAGE.)</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-7.5"></a><p></p>
<h2><span class="Bold">Labor and Delivery</span></h2>
<p class="First">The uterotonic effect of MethergineÂ is utilized after delivery to assist involution and decrease <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, shortening the third stage of labor.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2><span class="Bold">Nursing Mothers</span></h2>
<p class="First">Methergine<span class="Sup">Â®</span> (methylergonovine maleate) may be administered orally for a maximum of 1 week postpartum to control <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>. Recommended dosage is 1 tablet (0.2 mg) 3 or 4 times daily. At this dosage level a small quantity of drug appears in mothersâ€™ milk. Caution should be exercised when Methergine is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2><span class="Bold">Pediatric Use</span></h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.8"></a><p></p>
<h2><span class="Bold">Geriatric Use</span></h2>
<p class="First">Clinical studies of Methergine did not include sufficient number of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in response between the elderly and younger patients. In general dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">The most common adverse reaction is <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> associated in several cases with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> and/or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.  <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> has also been reported. <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> have occurred occasionally. Rarely observed reactions have included: <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, transient <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pains</span>, <span class="product-label-link" type="condition" conceptid="4292397" conceptname="Arteriospasm">arterial spasm</span> (coronary and peripheral), <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span>, <span class="product-label-link" type="condition" conceptid="4215499" conceptname="Water intoxication syndrome">water intoxication</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">leg cramps</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and foul taste.<span class="Sup">1</span></p>
<p>
		Â Â Â Â Â 
	There have been rare isolated reports of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, without a proven causal relationship to the drug product.</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1><span class="Bold">DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></span></h1>
<p class="First">Methergine<span class="Sup">Â®</span> (methylergonovine maleate) has not been associated with drug abuse or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> of either a physical or psychological nature.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">Symptoms of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> may include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the extremities, <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">rise in blood pressure</span>, in severe cases followed by <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
<p>
		Â Â Â Â Â 
	Because reports of overdosage with Methergine<span class="Sup">Â®</span> (methylergonovine maleate) are infrequent, the lethal doseÂ in humans has not been established. The oral LD<span class="Sub">50</span> (in mg/kg) for the mouse is 187, the rat 93, and the rabbitÂ 4.5.<span class="Sup">2</span> Several cases of accidental Methergine injection in newborn infants have been reported, and in such cases 0.2 mg represents an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of great magnitude. However, recovery occurred in all but one case following a period of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">hypertonicity</span> with jerking movements, and, in one case, a single <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsion</span>.</p>
<p>
		Â Â Â Â Â 
	Also, several children 1-3 years of age have accidentally ingested up to 10 tablets (2Â mg) with no apparent ill effects. A postpartum patient took 4Â tablets at one time in error and reported <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clamminess</span> as her only symptoms.</p>
<p>
		Â Â Â Â Â 
	Treatment of acute overdosage is symptomatic and includes the usual procedures of:</p>
<ol class="Arabic">
<li>removal of offending drug by inducing <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, gastric lavage, catharsis, and supportive <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>.<br>
</li>
<li>maintenance of adequate pulmonary ventilation, especially if <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> develop.<br>
</li>
<li>correction of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> with pressor drugs as needed.<br>
</li>
<li>control of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> with standard anticonvulsant agents.<br>
</li>
<li>control of peripheral <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span> with warmth to the extremities if needed.<span class="Sup">3</span>
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION</span></h1>
<p class="First">Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration.</p>
<p><span class="Bold">Intramuscularly</span></p>
<p>1 mL, 0.2 mg, after delivery of the anterior shoulder, after delivery of the placenta, or during the puerperium. May be repeated as required, at intervals of 2-4 hours.</p>
<p><span class="Bold">Intravenously</span></p>
<p>Dosage same as intramuscular. (See WARNINGS.)</p>
<p><span class="Bold">Orally</span></p>
<p>One tablet, 0.2 mg, 3 or 4 times daily in the puerperium for a maximum of 1 week.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First"><span class="Bold">Tablets</span></p>
<p>0.2 mg round, coated, orchid, branded â€œ78-54â€? one side, â€œSANDOZâ€? other side.</p>
<p>
		Â Â Â Â Â 
	Bottles of 100â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦..NDC 0078-0054-05</p>
<p><span class="Bold">Ampuls</span></p>
<p>1 mL size</p>
<p>
		Â Â Â Â Â 
	Boxes of 20â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦â€¦.NDC 0078-0053-03</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<h2><span class="Bold">Store and Dispense</span></h2>
<p class="First"><span class="Italics">Tablets</span>:  Store below 25Â°C (77Â°F); in tight, light-resistant container. </p>
<p><span class="Italics">Ampuls:</span>  Store in refrigerator, 2ÂºC-8Â°C (36Â°F-46Â°F). Protect from light. Administer only if solution is clear and colorless.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-13"></a><p></p>
<h1><span class="Bold">REFERENCES</span></h1>
<ol class="Arabic">
<li>Information on Adverse Reactions supplied by Medical Services Department, Novartis Pharmaceuticals, E. Hanover, N.J., based on computerized clinical reports.<br>
</li>
<li>Berde, B. and Schild, H.O.: <span class="Italics">Ergot Alkaloids and Related Compounds</span>, Springer-Verlag, New York, 1978, p. 810.<br>
</li>
<li>Treatment of Acute Overdosage. Novartis Consumer Health, Inc. Rx Products. Novartis, Medical Services Department.</li>
</ol>
<p class="First">T2006-91</p>
<p>REV: OCTOBER 2006
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	Printed in the U.S.A.
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	     5000981</p>
<p>5000982</p>
<p>Distributed by:</p>
<p>Novartis Pharmaceuticals Corporation</p>
<p>East Hanover, New Jersey  07936</p>
<p>Â© Novartis</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL </span></h1>
<p class="First"><span class="Bold">Package </span><span class="Bold">Label â€“ 0.2 mg Tablets</span></p>
<p>Rx Only 
		Â Â Â Â Â 
	
		Â Â Â Â Â 
	NDC 43063-147-06</p>
<p>MethergineÂ® (methylergonovine maleate) Tablets, USP</p>
<p>6 Tablets</p>
<div class="Figure"><img alt="43063147 label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=94c9b1cf-ae12-45f3-8fcb-708a922cbc10&amp;name=43063147.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METHERGINEÂ 		
					</strong><br><span class="contentTableReg">methylergonovine maleate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:43063-147(NDC:0078-0054)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLERGONOVINE MALEATE</strong> (METHYLERGONOVINE) </td>
<td class="formItem">METHYLERGONOVINE MALEATE</td>
<td class="formItem">0.2Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACACIA</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C RED NO. 7</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GELATIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>LACTOSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MALEIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM BENZOATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TALC</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">PURPLE (orchid) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">78;54;SANZOZ</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:43063-147-06</td>
<td class="formItem">6  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA006035</td>
<td class="formItem">11/19/1946</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2009<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>81bdaa55-49e8-4a2d-8ce6-26266b157a09</div>
<div>Set id: 94c9b1cf-ae12-45f3-8fcb-708a922cbc10</div>
<div>Version: 5</div>
<div>Effective Time: 20090618</div>
</div>
</div>Â <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
